10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment

September 13, 2017

First time 10-year prospective outcome data confirms clinical utility of MammaPrint for lymph node-negative and lymph node-positive patients MINDACT sub-study shows that even tumors less than 1cm in size can be aggressive with 24% reclassified by MammaPrint from low risk based on clinico-pathological factors to High Risk   IRVINE, CA and AMSTERDAM – 13 September…

Read more

Agendia’s MammaPrint Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

July 10, 2017

ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for 1-3 lymph node positive early-stage breast cancer patients Revised ASCO Guidelines mark the fourth positive international guideline update for MammaPrint…

Read more

Agendia’s MammaPrint recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update

July 6, 2017

IRVINE, CA and AMSTERDAM – 6 July 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics announces that the 15th St. Gallen International Breast Cancer Guidelines recently published in Annals of Oncology1 have recommended the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test for the third time to help guide treatment decision-making…

Read more

MammaPrint Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment

June 29, 2017

Retrospective analysis of patient samples from the prospective, randomized Stockholm Tamoxifen Trial demonstrates clinical utility of MammaPrint in identifying breast cancer patients with exceedingly low likelihood for late recurrence at 20-years MammaPrint Late Recurrence (20yr) Low Risk result identifies sub-group of patients with excellent survival after 20 years with little or no hormonal therapy, providing…

Read more